DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2016" drug pipelines to their offering.
This report provides comprehensive information on the therapeutic development for Thrombocythaemia Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocythaemia Myelofibrosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Thrombocythaemia Myelofibrosis Overview
- Therapeutics Development
- Pipeline Products for Thrombocythaemia Myelofibrosis - Overview
- Pipeline Products for Thrombocythaemia Myelofibrosis - Comparative Analysis
- Thrombocythaemia Myelofibrosis - Therapeutics under Development by Companies
- Thrombocythaemia Myelofibrosis - Therapeutics under Investigation by Universities/Institutes
- Thrombocythaemia Myelofibrosis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Thrombocythaemia Myelofibrosis - Products under Development by Companies
- Thrombocythaemia Myelofibrosis - Products under Investigation by Universities/Institutes
- Thrombocythaemia Myelofibrosis - Companies Involved in Therapeutics Development
- Celgene Corporation
- Gilead Sciences, Inc.
- Incyte Corporation
- JW Pharmaceutical Corporation
- Nippon Shinyaku Co., Ltd.
- Novartis AG
- Pfizer Inc.
For more information about this drug pipelines visit http://www.researchandmarkets.com/research/6pgc36/thrombocythaemia
Related Topics: Leukemia Drugs